Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sertraline in Paroxysmal Arterial Hypertension
NCT02641652Phase 4
Key facts
- Status
- Unknown
- Start
- Nov 2017
- Primary completion
- Jun 2018
- Sponsor
- University Hospital Olomouc
- Modality
- Small Molecules
- Drugs
- sertraline
- Conditions
- paroxysmal hypertension
01
Overview
Phase 4, randomised, double-blind trial in paroxysmal hypertension comparing Sertraline with Placebo (2 arms). Primary endpoints: Rate of paroxysmal hypertension symptoms cessation at 3 months and Rate of paroxysmal hypertension symptoms reduction at 3 months. Status: unknown.
02
Design
2 arms- Study design
- RandomizedDouble-blind
Sertraline
Sertraline as an add-on to chronic medication
Placebo
Placebo as an add-on to chronic medication
03
Who it enrols
Adults with hypertensive paroxysms in the past 6 months, excluding pregnant/breastfeeding women and those on serotonergic drugs, MAOIs, or dopamine antagonists.
04
Endpoints
Primary
Rate of paroxysmal hypertension symptoms cessation
Rate of paroxysmal hypertension symptoms reduction
Secondary
Fall of mean office and ambulatory systolic and diastolic blood pressure
Side effects of the treatment
Beyond the preview
Go deeper on NCT02641652.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02641652.